scholarly journals A Phase II Clinical Study of mFOLFOX6 /XELOX as Adjuvant Chemotherapy after Curative Resection of Stage III Colon Cancer: The FACOS Study

2016 ◽  
Vol 24 (1) ◽  
pp. 17-22 ◽  
Author(s):  
Keiichiro Ishibashi ◽  
Kensuke Kumamoto ◽  
Keiji Koda ◽  
Hiroyuki Kato ◽  
Genichi Nishimura ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Clinical Study ◽  
Adjuvant Chemotherapy ◽  
Phase Ii ◽  
Curative Resection ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Phase Ii Clinical Study

Survival results of hepatectomy followed by adjuvant chemotherapy with three months of capecitabine plus oxaliplatin for colorectal cancer liver metastases: A multicenter phase II study.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 866-866 ◽  
Author(s):  
Hironaga Satake ◽  
Hiroki Hashida ◽  
Hiroaki Tanioka ◽  
Yasuhiro Miyake ◽  
Shinichi Yoshioka ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Liver Metastases ◽  
Phase Ii ◽  
Curative Resection ◽  
Completion Rate ◽  
Colorectal Cancer Liver Metastases ◽  
Oral Capecitabine ◽  
Stage Iii Colon Cancer

866 Background: Hepatic resection is one of the treatment strategies for resectable colorectal cancer liver metastases (CLM). The role of neoadjuvant and adjuvant chemotherapy in the management of initially resectable CLM is still unclear. Adjuvant chemotherapy consisting of capecitabine plus oxaliplatin (CapeOx) appears to be equivalent to FOLFOX in patients with stage III colon cancer. Furthermore, the IDEA collaboration reported that adjuvant chemotherapy with the three months of CapeOx after curative resection for stage III colon cancer has equivalent efficacy to adjuvant chemotherapy for 6 months. We conducted a multi-institutional, single-arm, phase II trial to confirm the feasibility of the three months of adjuvant CapeOx for post curative resection of CLM. Methods: Patients received one course of capecitabine followed by four courses of CapeOx for a total five courses (15 weeks) as adjuvant chemotherapy after curative resection of CLM. Oral capecitabine was given with 1,000 mg/m2 twice daily for 2 weeks in a 3-week cycle, and CapeOx consisted of oral capecitabine plus oxaliplatin 130 mg/m2 on day 1 in a 3-week cycle. The primary endpoint was completion rate of adjuvant chemotherapy. We set a threshold completion rate of protocol treatment of 45% and an expected completion rate of 70%. Given a one-sided α of 0.1 and statistical power of 80%, a minimum of 25 patients was required. Results: From May 2013 to November 2015, Twenty-eight patients were enrolled from six institutions: median age 69.5y, 54% male, 78.5% left-sided primary. Of the patients, 15 were synchronous metastases and 13 were metachronous. The locations of the metastases were unilobar in 20 patients and bilobar in 8. The mean number of lesions resected was two (range, 1 to 4). Among the 28 patients, 20 (71.4%: 95% CI, 53.6 to 89.3%) completed the protocol treatment. The most common grade 3/4 toxicities were neutropenia (29%). No treatment related death was observed. With a median follow-up period of 36 months (range 15-53months), 3 year-relapse free survival was 75.3%. Conclusions: The three months of adjuvant CapeOx is tolerable for post curative resection of CLM. Clinical trial information: 000011164.

scholarly journals Safety Analysis of Folfox as Adjuvant Chemotherapy for Stage III Colon Cancer in North Japan Multicenter Phase II Study (NORTH/HGCSG1003)

2014 ◽  
Vol 25 ◽  
pp. ii95
Author(s):  
Takahashi Norihiko ◽  
Yuki Satoshi ◽  
Fukushima Hiraku ◽  
Shichinohe Toshiaki ◽  
Sasaki Takahide ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Safety Analysis ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Multicenter Phase

A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6/CAPOX for stage III colon cancer treatment after D2/D3 lymphadenectomy

Surgery Today ◽  
2019 ◽  
Vol 49 (6) ◽  
pp. 498-506 ◽  
Author(s):  
Kazuhiko Yoshimatsu ◽  
Keiichiro Ishibashi ◽  
Keiji Koda ◽  
Hajime Yokomizo ◽  
Noritaka Oda ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Treatment ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Stage Iii ◽  
D3 Lymphadenectomy ◽  
Stage Iii Colon Cancer ◽  
Multicenter Phase
Sign in / Sign up

Export Citation Format

Share Document